NASDAQ:CTNM Contineum Therapeutics Q1 2026 Earnings Results & Report $8.35 -0.07 (-0.83%) As of 11:02 AM Eastern This is a fair market value price provided by Massive. Learn more. Contineum Therapeutics beat analyst earnings expectations in its Q1 2026 results, released May 5, 2026. The company reported EPS of -$0.39 versus the -$0.55 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ1 2026Report DateMay 5, 2026TimeBefore Market OpensConference Call4:00 PM ET Contineum Therapeutics EPS ResultsActual EPS-$0.39Consensus EPS -$0.55Beat/MissBeat by +$0.16One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersContineum Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsContineum Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled on Friday, October 30, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Contineum Therapeutics Q1 2026 Earnings FAQ Did Contineum Therapeutics beat earnings estimates for Q1 2026? Contineum Therapeutics (NASDAQ:CTNM) reported earnings of -$0.39 per share for Q1 2026, beating the consensus estimate of -$0.55. The report was announced on Tuesday, May 5, 2026. When is Contineum Therapeutics' next earnings date? Contineum Therapeutics' next earnings date is estimated for Thursday, October 29, 2026. MarketBeat tracks confirmed and estimated earnings dates for Contineum Therapeutics on the company's earnings history page. Contineum Therapeutics Earnings HeadlinesContineum drops 25% on mixed Bristol Myers IPF data; Stifel keeps Buy ratingOctober 12 at 12:38 PM | finance.yahoo.comContineum Therapeutics Shares Surge 27% After Bristol Myers Squibb Reports Positive Phase 3 Trial ResultsOctober 12 at 12:38 PM | msn.comWall Street legend reveals his top AI stock before Oct. 20Marc Chaikin, the 60-year Wall Street veteran behind the Power Gauge rating system, has flagged a new AI stock ahead of October 20. His system has spotted at least seven of the top 10 performers every year since 2016, including all ten in the 2022 bear market and every member of the Magnificent Seven before their run higher. Now Chaikin's Power Gauge is turning bullish on an under-the-radar company tied to next-generation AI data centers built under Executive Order 14363, technology he says uses 99 percent less electricity and space while offering far greater computing power.October 14 at 1:00 AM | Chaikin Analytics (Ad)All You Need to Know About Contineum Therapeutics, Inc. (CTNM) Rating Upgrade to BuyOctober 12 at 12:38 PM | finance.yahoo.comContineum Therapeutics, Inc. (NASDAQ:CTNM) Stock Now Rated "Moderate Buy" by Sell-Side BrokeragesOctober 8, 2026 | americanbankingnews.comAdherex Technologies (NASDAQ:FENC) vs. Contineum Therapeutics (NASDAQ:CTNM) Critical ContrastOctober 5, 2026 | americanbankingnews.comSee More Contineum Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Contineum Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Contineum Therapeutics and other key companies, straight to your email. Email Address About Contineum TherapeuticsContineum Therapeutics (NASDAQ:CTNM) is a clinical-stage biotechnology company focused on developing medicines for diseases of the central nervous system. The company’s research is centered on therapeutics designed to promote remyelination, the repair of damaged myelin that supports nerve function, and to address neuroinflammation and other mechanisms involved in neurological disorders. Contineum’s pipeline includes PIPE-307, an oral, selective M1 muscarinic receptor antagonist being investigated for its potential to promote remyelination in multiple sclerosis. The company is also developing PIPE-791, an oral small-molecule lysophosphatidic acid receptor 1 antagonist intended for central nervous system and fibrotic diseases. Its programs are based on research into biological pathways that may contribute to nerve damage, impaired repair and disease progression. The company was formerly known as Pipeline Therapeutics and is based in San Diego, California. Contineum is conducting clinical development through studies involving patients with neurological and other serious diseases, although specific geographic coverage and leadership details may change as the company advances its programs.View Contineum Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles A Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American BusinessTax Credit Turmoil: Why Enphase and SolarEdge Face a Tough RoadSurgical Precision, Sustainable Returns: Johnson & Johnson Secures Its Cash Flow RunwayJPMorgan Earnings Miss Estimates But Reveal Broad-Based StrengthAmazon's $220 Billion AI Bet Is Getting Bigger—Can Earnings Justify the Spending?Venezuela's Oil Revival Is Gaining Momentum—3 Energy Stocks Positioned to Benefit Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
